Showing 7491-7500 of 8692 results for "".
- Study: Botanical Gummies Show Promise for Thinning Hairhttps://practicaldermatology.com/news/study-botanical-gummies-show-promise-thinning-hair/2468582/A recent 6-month study found that a daily gummy supplement with B vitamins, zinc, and botanicals improved hair density, strength, and perceived hair quality in women with thinning hair. Researchers for the double-blind, placebo-controlled trial included 65 healthy female participants aged
- First Patient Dosed in Phase 3 Trial of Rapamycin for Microcystic LMshttps://practicaldermatology.com/news/first-patient-dosed-phase-3-trial-rapamycin-microcystic-lms/2468559/Palvella Therapeutics, Inc. announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of its 3.9% rapamycin anhydrous gel, QTORIN™ rapamycin, for the treatment of microcystic lymphatic malformations (LMs). "Micro
- Rademikibart 'Could Be Incredibly Important for Type 2'https://practicaldermatology.com/news/rademikibart-could-be-incredibly-important-type-2/2468551/A second-generation IL-4Rα inhibitor known as rademikibart shows promise for further elevating the standard of care for type 2 inflammatory conditions in the future, Dr. Christopher Bunick said during a presentation at the 44th Annual Fall Clinical Dermatology Conference. Dr. Bunick showed
- FDA Approves Emrosi for Rosaceahttps://practicaldermatology.com/news/fda-approves-emrosi-rosacea-treatment/2468543/The US Food and Drug Administration (FDA) has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) as a treatment for inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, Journey Medical (in partnership with Dr.
- CeraVe Expands into Haircare with Launch of Anti-Dandruff and Gentle Hydrating Productshttps://practicaldermatology.com/news/cerave-expands-haircare-launch-anti-dandruff-and-gentle-hydrating-products/2468510/CeraVe has announced the launch of Anti-Dandruff and Gentle Hydrating Products, leadin
- 'Me & My Inner Circle' Launches on World Psoriasis Dayhttps://practicaldermatology.com/news/me-my-inner-circle-launches-world-psoriasis-day/2468497/October 29 is World Psoriasis Day, and Almirall recognized the occasion by launching an awareness campaign called “Me & My Inner Circle,” with the support of the International Federation of Psoriasis Associations (IFPA), the company announced. The campaign features Alma, representing a
- Positive Results for Guselkumab for Moderate PsO Patientshttps://practicaldermatology.com/news/positive-results-guselkumab-moderate-pso-patients/2468490/Guselkumab treatment resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, according to data presented at the 44th Annual Fall Clinical Dermatology Conferenc
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- Dupilumab Improves Chronic Spontaneous Urticaria Symptomshttps://practicaldermatology.com/news/dupixent-improves-chronic-spontaneous-urticaria-symptoms/2468471/Dupixent® (dupilumab) significantly reduced itch and hive activity in patients with chronic spontaneous urticaria, according to phase 3 trial data presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts. In a pre
- Verrica To Share Phase 2 Results for VP-315 in BCC Treatment at Fall Clinicalhttps://practicaldermatology.com/news/verrica-share-phase-2-results-vp-315-bcc-treatment-fall-clinical/2468470/Verrica Pharmaceuticals announced today that two abstracts featuring positive topline results from their phase 2 study of VP-315 for the treatment of basal cell carcinoma (BCC) will be presented at the 2024 Fall Clinical Dermatology Conference. The presentations will focus on safety, tole